Consistent with these findings, Corkery and others found that depletion of PRP4K in multiple breast and ovarian cancer cell lines resulted in decreased sensitivity to paclitaxel, and whereas control cells arrested in metaphase and underwent apoptosis, PRP4K-depleted cells underwent “mitotic slippage” entering interphase without cell division (Corkery et al., 2015b). Here, PRP4K is linked to ovarian carcinoma.